A new lab-on-a-chip HIV testing device could make testing in developing nations easier and more affordable. UC Davis biomedical engineer Alexander Revzin developed the microfluidic device, which uses antibodies to “capture” white blood cells called T-cells that are affected by HIV. In addition to physically binding these cells, the test detects the types and levels of cytokines, or inflammatory proteins, released by the cells. Revzin’s team collaborated with UCLA electrical engineer Aydogan Ozcan to integrate an antibody microarray with a lens-free holographic imaging device that takes only seconds to count the number of captured cells and amount of secreted cytokine molecules. The test returns results six to 12 times faster than traditional approaches and tests six parameters simultaneously using a small blood sample. The team published its results in the May 2010 issue of Analytical Chemistry. UC Davis professor Alexander Revzin has developed a lab-on-a-chip device for HIV testing. The microfluidic device uses antibodies to physically bind T-cells affected by HIV and to detect the types and levels of cytokines released by the cells. The test potentially can be used at the point of care in the developing world and in resource-poor areas. (Image: Gulnaz Stybayeva, UC Davis) With further refinements, the test will have wide potential use for multiparametric blood analysis performed at the point of care in the developing world and other impoverished areas. Its affordability will also make it an attractive option in wealthier areas. Revzin has filed for a patent and is looking for ways to bring his test into clinical use. “In addition to HIV testing and monitoring, this device will be useful for blood transfusions, where the safety of blood is frequently in question,” Revzin said. The most accurate and effective way to diagnose and monitor HIV infection involves counting two types of T-cells, calculating the ratio between the two categories, and measuring cytokines. Scientists do this using a method called flow cytometry, which requires an expensive machine and several highly trained specialists. Health care workers and AIDS activists in the developing world have called for less expensive, more easily performed tests. “While the point of care field focuses on detection of single parameter (e.g., CD4 counts), we believe that the simplicity of the test need not compromise information content. So, we set out to develop a test that could be simple and inexpensive but would provide several parameters based on a single injection of a small blood volume,” explained Revzin. The HIV test addresses two distinct challenges of blood analysis: (1) capturing the desired cell type from blood, which contains multiple cell types, and (2) connecting the desired blood cell type with secreted cytokines. The test consists of polymer film imprinted with an array of miniature spots. Each spot contains antibodies specific to the two kinds of T-cells (CD4 and CD8) and three types of cytokines printed in the same array. When the blood flowed across the antibody spots, T-cells stopped and stuck on the spots. Each T-cell type was captured next to antibody spots specific for the cytokines they might produce. When antibodies activated the cells, spots adjacent to the cells captured the cytokines they secreted. This connected a specific T-cell subset to its secreted cytokines. The visible color intensity of antibody spots revealed differences in cytokine production by T-cells. Ozcan’s lens-free on-chip imaging allowed the scientists to rapidly image and count T-cell arrays without using any lenses or mechanical scanning. Analysis of CD4 and CD8 T-cell numbers, the CD4:CD8 ratio and three secreted cytokines took only seconds. In the future, Revzin envisions adding microarrays to the test that can detect proteins from the HIV and hepatitis C viruses. For more information, visit: www.ucdavis.edu